Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290357 | 0.90 | MLYCD (0.64) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2990091 | 0.90 | MLYCD (0.51) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2989841 | 0.87 | MLYCD (0.68) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2985736 | 0.86 | MLYCD (0.72) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2985881 | 0.86 | MLYCD (0.67) | MLYCDALOX5ALDH1A1HPGDUSP2 | |
| SCHEMBL2990245 | 0.85 | MLYCD (0.64) | MLYCDALOX5ALDH1A1HPGDUSP2 | |
| SCHEMBL2991945 | 0.84 | MLYCD (0.69) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2982425 | 0.84 | MLYCD (0.64) | MLYCDALOX5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2987638 | 0.83 | MLYCD (0.61) | MLYCDALOX5ALDH1A1HPGDUSP2 | |
| SCHEMBL2994595 | 0.83 | MLYCD (0.67) | MLYCDALOX5ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | MLYCD 2597/4885ALOX5 17/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.